Consolidated statement of comprehensive income for the year ended 31 December 2015 2015 2014 Notes m m Revenue 4 10.8 Cost of sales 4.3 Gross profit 6.5 Research and development costs 46.8 38.6 Sales and marketing 13.5 Administrative expenses 13.7 7.2 Other gains 9 1.1 Operating loss 7 66.4 45.8 Finance income 6 3.5 1.9 Share of profit loss of joint venture 16 0.1 0.1 Loss before tax 62.8 44.0 Taxation 10 12.8 8.9 Loss for the financial year 50.0 35.1 Loss attributable to: Owners of Circassia Pharmaceuticals plc 49.9 35.1 Noncontrolling interests 0.1 Loss for the financial year 50.0 35.1 Items that may be subsequently reclassified to profit or loss: Currency translation differences attributable to: Owners of Circassia Pharmaceuticals plc 27 3.1 Total other comprehensive income for the year 3.1 Total comprehensive expense for the year 46.9 35.1 Total comprehensive expense attributable to: Owners of Circassia Pharmaceuticals plc 46.8 35.1 Noncontrolling interests 0.1 Total comprehensive expense for the year 46.9 35.1 Loss per share attributable to owners of the parent during the year expressed in per share Basic and diluted loss per share Loss per share from continuing operations 11 0.20 0.21 The results for the financial years above are derived entirely from continuing operations.
The Company has elected to take the exemption under section 408 of the Companies Act 2006 not to present the parent company profit and loss account.
The loss for the parent company for the year was 3.2 million 2014: profit 0.5 million.
The notes on pages 92 to 117 are an integral part of these consolidated financial statements.
Circassia Pharmaceuticals plc Annual report and accounts 2015 86
